Trimel Pharmaceuticals Facility Receives GMP Compliance Designation
Trimel intends to use the Dunwin facility to manufacture clinical supplies for both of its CompleoTRT and TBS-2 (Anorgasmia) products as well as the balance of its pipeline including those compounds under development with the TriVair pulmonary delivery system. Trimel has demonstrated to Health Canada that the activities it conducts at its Dunwin facility conform to the Food and Drugs Act and its associated regulations.
"Having Health Canada approve our facility is an important validation of our business strategy." said Bruce D. Brydon, Chairman and Chief Executive Officer of Trimel. "Trimel has now achieved the first step toward the commercial supply of our products with the strictest adherence to quality."